The European Patent Office (EPO) has published patent application EP4709723A1, detailing the invention of isoxazolidines as inhibitors of Ripk1 for therapeutic applications. The applicant is Genzyme Corporation, and the publication date is March 18, 2026. This patent application covers the chemical structure of the compounds and their use in treating conditions where Ripk1 inhibition is beneficial.

This publication represents a new intellectual property filing and does not impose immediate compliance obligations on regulated entities. However, it is relevant for pharmaceutical and drug manufacturers monitoring the patent landscape for new therapeutic agents. Companies involved in Ripk1 inhibitor research or development should review this patent to assess potential overlaps or licensing opportunities.